A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
-
Artiva Clinical Trial Site, Tucson, Arizona, United States, 85748
Artiva Clinical Trial Site, Aventura, Florida, United States, 33180
Artiva Clinical Trial Site, Plantation, Florida, United States, 33324
Artiva Clinical Trial Site, Willowbrook, Illinois, United States, 60527
Artiva Clinical Trial Site, Charlotte, North Carolina, United States, 28625
Artiva Clinical Trial Site, Arlington, Texas, United States, 76012
Artiva Clinical Trial Site, Houston, Texas, United States, 83506
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Artiva Biotherapeutics, Inc.,
Michael Saddekni, M.D., PgDip, BCMAS, STUDY_DIRECTOR, Artiva Therapeutics
2029-01